| 论文作者 |
Hou, ZM; Huang, SS; Mei, ZJ; Chen, LL; Guo, JC; Gao, YY; Zhuang, Q; Zhang, XB; Tan, QL; Yang, T; Liu, Y; Chi, YN; Qi, LFR; Jiang, T; Shao, XF; Wu, Y; Xu, XJ; Qin, J; Ren, RB; Tang, HR; Wu, DL; Li, ZF |
| 摘要 |
Prostate cancer continuously progresses following deprivation of circulating androgens originating from the testis and adrenal glands, indicating the existence of oncometabolites beyond androgens. In this study, mass-spectrometry-based screening of clinical specimens and a retrospective analysis on the clinical data of prostate cancer patients indicate the potential oncogenic effects of progesterone in patients. High doses of progesterone activate canonical and non-canonical androgen receptor (AR) target genes. Physiological levels of progesterone facilitate cell proliferation via GATA2. Inhibitors of 3(3-hydroxysteroid dehydrogenase 1 (3(3 beta HSD1) has been discovered and shown to suppress the generation of progesterone, eliminating its transient and accumulating oncogenic effects. An increase in progesterone is associated with poor clinical outcomes in patients and may be used as a predictive biomarker. Overall, we demonstrate that progesterone acts as an oncogenic hormone in prostate cancer, and strategies to eliminate its oncogenic effects may benefit prostate cancer patients. |
官方微信
